The unique structural design of amivantamab with simultaneous binding to both EGFR and MET with addition of a low fructose backbone for enhanced ADCC provide increased selectivity and efficacy with decreased toxicity compared to other targeted therapies for EGFR exon20ins NSCLC [53]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.